HemaB

Hemab is a biotech focused on rare bleeding disorders. Lead asset HMB-001 is a bispecific antibody for potential once-monthly prophylactic treatment.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2026
Stage of Initial Investment
Series A
Initial Investment Year
2021
Hema B Hover Image